http://hdl.handle.net/11054/4 Research output collection Sat, 12 Sep 2026 05:11:10 GMT 2026-09-12T05:11:10Z http://hdl.handle.net/11054/3244 Title: Real world evidence on the diagnostic journey of Australian metastatic triple negative breast cancer (mTNBC) patients (Poster). Tue, 01 Jan 2019 00:00:00 GMT http://hdl.handle.net/11054/3244 2019-01-01T00:00:00Z http://hdl.handle.net/11054/3243 Title: Health care resource utilisation for patients with metastatic triple negative breast cancer (mTNBC) in the real world clinical setting: An observational breast cancer (OBTAIN) study from Australia (Poster). Abstract: Compared to other breast cancers, triple-negative breast cancers (TNBC) are more chemo-sensitive. Therefore, chemotherapy forms the mainstay treatment option for TNBCs. Notably, it is well established that these cytotoxic treatments result in several adverse events which in turn results in higher health care resource utilization (HCRU). However, there is scant information on the HCRU for TNBC patients. This observational cohort study aims to further understand the HCRU for TNBC patients the real world setting. Mon, 01 Jan 2018 00:00:00 GMT http://hdl.handle.net/11054/3243 2018-01-01T00:00:00Z http://hdl.handle.net/11054/3242 Title: Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting. Abstract: Background: Triple-negative breast cancer is a biologically aggressive disease that accounts for 15% of all breast cancers, of which around 4-5% are metastatic (mTNBC) at diagnosis. Notably, there is no standard of care for mTNBC in the first line (1L) setting. This, in addition to higher relapse rates and poor long-term survival, warrants evaluation of real-world treatment patterns, especially in the 1L setting, to better inform on clinical outcomes. Methods: This observational, retrospective, chart review study included a cohort of twenty-six mTNBC patients from six different sites Australia, who commenced 1L treatment between July 1, 2012 and June 30, 2015. Medical records of eligible patients were abstracted using electronic case report forms after gaining relevant ethics approvals. Data on treatment patterns and clinical outcomes in the 1L setting were then collected from the index date until the end of data abstraction or death. The index date is defined as the date of initiation of 1L systemic therapy for mTNBC. Results: In the 1L setting, patients that received combination (52%) chemotherapy was slightly higher than single-agent (48%) chemotherapy. The commonest combination used was Carboplatin-Gemcitabine (12%), and the most common monotherapy was Nab-Paclitaxel (24%). The overall response rate and disease control rate were estimated to be 32% and 60% in the 1L setting. The median duration of treatment and the median time to next line of therapy were calculated to be 98 days and 12.45 (95% CI 2.79, 20.30) months respectively. Importantly, the median progression free survival (sensitivity analysis) and the median overall survival were estimated to be 3.17 (95% CI 1.91, 5.09) and 10.41 (95% CI 5.36, 16.53) months respectively. Conclusions: Chemotherapy is currently the mainstay of treatment for mTNBC. However, disease progression and chemo-related toxicities warrant stratified use of more efficacious and tolerable treatment options, especially in the 1L setting. Results from this study could be useful in comparing the efficacy and cost effectiveness of these emerging targeted and immuno-therapies outside the clinical trial setting. Tue, 01 Jan 2019 00:00:00 GMT http://hdl.handle.net/11054/3242 2019-01-01T00:00:00Z http://hdl.handle.net/11054/3241 Title: A Victorian clinician-based survey on current practices for breast cancer staging in pregnancy (Poster). Abstract: Background/aims: Incidence of cancer during pregnancy is rising.1 There is limited evidence, and no national guidelines regarding when to perform staging and which imaging modalities are safe and accurate during pregnancy. This study assesses current Victorian clinician practices for staging of pregnant women with breast cancer. Method(s): A study specific survey was administered to medical oncologists, surgeons, radiation oncologists, radiologists and specialty trainees at breast multidisciplinary meetings across regional and metropolitan Victoria. The questionnaire assessed clinician level of work experience, perceived indications for staging, and preferred imaging modalities in breast cancer patients who are pregnant. Result(s): One hundred three questionnaires were completed with an overall response rate of 87%. Eighty-seven cancer specialists (35 surgeons, 33 medical oncologists, 12 radiologists, seven radiation oncologists) and 16 trainees completed the survey. 76(74%) of clinicians had worked in their field for >6 years and 65(63%) had treated at least one pregnant woman with breast cancer. Two per cent of clinicians would not stage during pregnancy. Sixty-one (59%) would stage in locally advanced or inflammatory, 56(54%) in clinical node involvement, 79(77%) if strongly suspicious of metastatic disease. Fifty per cent and 59% of clinicians would order chest X-ray and liver ultrasound, respectively. Less frequently selected tests included CT chest (11%), whole spine MRI (8%), whole body MRI (8%), whole body bone scan (5%), and CT abdomen and pelvis (1%).87%of clinicians would like local or national guidelines in this area. Conclusion(s): There is variability in clinical practice for staging pregnant women with breast cancer. The majority of clinicians surveyed believe guidelines are warranted. We plan to develop consensus guidelines on the use of imaging for staging of pregnant women with breast cancer. Tue, 01 Jan 2019 00:00:00 GMT http://hdl.handle.net/11054/3241 2019-01-01T00:00:00Z